For US Healthcare Professionals only
PRESCRIBINGINFORMATION REQUEST
SAMPLES
NUZYRA is indicated for the treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in adults caused by select susceptible microorganisms.
NUZYRA PHARMACY NETWORK FINDER
Use the finder below to locate pharmacies that carry NUZYRA tablets.
When preparing to provide a patient with a NUZYRA prescription for tablets, please select a pharmacy from the search results below, or from one of the pharmacies listed here.
You can e-prescribe, phone in, or fax their prescriptions directly to any pharmacy in the NUZYRA Pharmacy Network.
* This information is current as of 09/22/2023.
NUZYRA is available at pharmacies in the NUZYRA Pharmacy Network.
Paratek does not recommend or prefer the use of one pharmacy over another.
Inventory may vary. Check with your local pharmacy for availability and additional guidance.
Pharmacies near you
There don't seem to be any pharmacies in your selected radius. Please see the list of mail order pharmacies below, or call
NUZYRA CENTRAL ™ at 1-877-4-NUZYRA (1-877-468-9972).
NUZYRA Pharmacy Network
All pharmacies are able to provide same-day or next-day delivery of NUZYRA.
Click the button to download the list below.
Walgreens
Walgreens Pharmacy at Piedmont Hospital
35 Collier Rd NW Suite 100
Atlanta, Georgia 30309
Phone 404-350-9772
Fax 404-355-8966
Community, a Walgreens Pharmacy
28311 Marguerite Parkway, B-1
Mission Viejo, California 92692
Phone 949-538-3038
Fax 949-538-3039
Walgreens Pharmacy at Baptist Beaumont
3080 College Street
Beaumont, Texas 77701
Phone 409-813-1206
Fax 409-813-1261
Community, a Walgreens Pharmacy
115A N Euclid Ave
Saint Louis, Missouri 63108
Phone 314-454-6676
Fax 314-367-1881
Community, a Walgreens Pharmacy
912 W Belmont Ave
Chicago, Illinois 60657
Phone 773-665-8990
Fax 773-665-9766
https://www.walgreens.com/topic/pharmacy/specialty-pharmacy.jsp
CVS
Phone 866-833-3752 ext 1036927
Fax 800-323-2445
www.cvsspecialty.com
Note: Prescriptions accepted via fax only
OR
e-prescribe to:
Caremark Illinois Specialty Pharmacy, LLC., dba CVS Caremark
800 Biermann Court, Suite B
Mount Prospect IL 60056
866-833-3752 Ext 1036927
Fax: 909-799-6462
Kroger Specialty Pharmacy
3200 Lake Emma Rd Ste 1000
Lake Mary, Florida 32746
(855) 274-1694
Fax: (855) 819-6922
www.krogerspecialtypharmacy.com
PANTHERx
24 Summit Park Dr.
Pittsburgh, PA 15275
Phone 855-726-8479
Fax 855-246-3986
https://www.pantherxrare.com
NUZYRA® (omadacycline) is a tetracycline-class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms:
Community-Acquired Bacterial Pneumonia (CABP) caused by the following:
Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by the following:
Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Enterococcus faecalis, Enterobacter cloacae, and Klebsiella pneumoniae.
USAGE
To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline-class antibacterial drugs, or to any of the excipients.
WARNINGS AND PRECAUTIONS
Mortality imbalance was observed in the CABP clinical trial with eight deaths (2%) occurring in patients treated with NUZYRA compared to four deaths (1%) in patients treated with moxifloxacin. The cause of the mortality imbalance has not been established. All deaths, in both treatment arms, occurred in patients > 65 years of age; most patients had multiple comorbidities. The causes of death varied and included worsening and/or complications of infection and underlying conditions. Closely monitor clinical response to therapy in CABP patients, particularly in those at higher risk for mortality.
The use of NUZYRA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.
The use of NUZYRA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.
Hypersensitivity reactions have been reported with NUZYRA. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline-class antibacterial drugs. NUZYRA is structurally similar to other tetracycline-class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline-class antibacterial drugs. Discontinue NUZYRA if an allergic reaction occurs.
Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.
NUZYRA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions, including photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests), have been reported for other tetracycline-class antibacterial drugs, and may occur with NUZYRA. Discontinue NUZYRA if any of these adverse reactions are suspected.
Prescribing NUZYRA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation.
DRUG INTERACTIONS
Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA.
Absorption of tetracyclines, including NUZYRA is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations.
USE IN SPECIFIC POPULATIONS
Lactation: Breastfeeding is not recommended during treatment with NUZYRA.
Please see Full Prescribing Information for NUZYRA.